Liquidia Corporation (LQDA) Earnings Call Analysis

NASDAQ · Healthcare · Biotechnology

21/25

Growth 5 Margin 5 Expansion 4 Platform 3 Financial 4

latest quarter score

Earnings Reports

21
Liquidia (LQDA) Q2 2026: $170M YUTREPIA Sales Fuel 31% Quarter-over-Quarter Growth and Pipeline Expansion
August 12, 2026
21
LQDA Q1 2026: Utrepia Drives 44% Sequential Sales Growth, Anchoring Category Leadership
May 11, 2026
19
Liquidia (LQDA) Q4 2025: Eutrepia Captures 17% Market Share, Outpaces Inhaled Prostacyclin Growth
March 05, 2026
17
Liquidia (LQDA) Q3 2025: Eutropia Captures 75% of Inhaled Prostacyclin Market Growth
November 03, 2025
14
Liquidia (LQDA) Q2 2025: Eutrepia Prescriptions Top 900 in 11 Weeks, Accelerating Prostacyclin Market Disruption
August 12, 2025
5
Liquidia (LQDA) Q1 2025: 48% G&A Surge Signals Full-Scale Launch Readiness for Utrepia
July 07, 2025
7
Liquidia Corporation (LQDA) Full Year 2024: $100M Financing Boost and Imminent FDA Approval Set Stage for Market Entry
March 19, 2025

Browse all companies